Experience with UroBest® in patients with acute cystitis
- Authors: Kyzlasov P.S.1, Neymark B.A.2, Kuzmenko A.V.3, Abuev G.G.1, Gyaurgiev T.A.3, Kuzmenko G.A.3
-
Affiliations:
- A.I. Burnazyan SRC FMBC, FMBA of Russia
- Altai State Medical University of the Ministry of Health of the Russian Federation
- Voronezh State Medical University named after N.N. Burdenko
- Issue: No 4 (2024)
- Pages: 41-47
- Section: Original Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/636278
- DOI: https://doi.org/10.18565/urology.2024.4.41-47
- ID: 636278
Cite item
Open Access
Access granted
Abstract
Aim. To evaluate the efficacy and safety of UroBest® complex in sachets for combined therapy of patients with acute cystitis in comparison with products of similar composition.
Materials and Methods. The randomized multi-center study included 90 patients with acute cystitis aged 18 to 49 years who were treated at the clinical bases of SRC FMBC, FMBA of Russia, Moscow, Russia, Altai State Medical University and Voronezh State Medical University named after N.N. Burdenko. Patients of all groups received Fosfomycin trometamol in a dosage of 3g once, at night. Depending on the additional drug received, they were divided into 3 groups of 30 patients each. In group 1, they took UroBest® 1 sachet daily for 7 days from the first day of therapy, NefroBest-N® one capsule 2 times a day for 1 month also from the first day of therapy, in combination with UroBest® complex in the first week. In group 2, UroBest® 1 sachet daily for 7 days was administered, while in group 3, biologically active supplement (BAA) "Uronext"® 1 sachet daily for 7 days was given. The study included 4 control points, where the degree and dynamics of changes in laboratory parameters (urinalysis, complete cell count, urine culture with determination of sensitivity to antibiotics), quality of life according to the questionnaire, and pain intensity according to the visual analogue scale (VAS) were assessed, as well as the drug tolerability based on the analysis of adverse events.
Results. The efficacy and safety data were evaluated. Administration of complex preparations with extracts of medicinal plants as an additional to antibacterial therapy led to significant improvement of all parameters, except for the level of leucocytes in the complete cell count. The most pronounced improvement was observed in groups 1, and lesser improvement was noted in group 2. One patient in group 3 had an adverse event, which was resolved spontaneously.
Conclusion. UroBest® has a favorable efficacy and safety profile. According to our experience, combination of UroBest® and NefroBest-N® complexes leads to more pronounced positive changes in laboratory parameters and patient's condition according to the questionnaires compared to UroBest® as monotherapy and, to an even greater extent, to the biologically active supplement UroNext®.
Full Text
About the authors
P. S. Kyzlasov
A.I. Burnazyan SRC FMBC, FMBA of Russia
Email: dr.kyzlasov@mail.ru
ORCID iD: 0000-0003-1050-6198
PhD, MD, Head of the Center of Urology and Andrology
Russian Federation, MoscowB. A. Neymark
Altai State Medical University of the Ministry of Health of the Russian Federation
Email: neimark.b@mail.ru
ORCID iD: 0000-0001-8009-3777
PhD, MD, Professor of the Department of Urology and Andrology with the Course of Additional Postgraduate Education
Russian Federation, BarnaulA. V. Kuzmenko
Voronezh State Medical University named after N.N. Burdenko
Email: kuzmenkoav09@yandex.ru
ORCID iD: 0000-0002-7927-7015
PhD, MD, Associate Professor, Head of the Department of Urology
Russian Federation, VoronezhG. G. Abuev
A.I. Burnazyan SRC FMBC, FMBA of Russia
Author for correspondence.
Email: abuev.urology@gmail.com
Urologist, PhD Student at the Department of Urology and Andrology
Russian Federation, MoscowT. A. Gyaurgiev
Voronezh State Medical University named after N.N. Burdenko
Email: gta001100@yandex.ru
PhD, Associate Professor at the Department of Urology
Russian Federation, VoronezhG. A. Kuzmenko
Voronezh State Medical University named after N.N. Burdenko
Email: KGA00110009@yandex.ru
ORCID iD: 0000-0002-6308-5211
4th-Year Student of the Pediatric Faculty
Russian Federation, VoronezhReferences
- Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am. 1997 Sep;11(3):551–581. doi: 10.1016/s0891-5520(05)70373-1. PMID: 9378923.
- Kulchavenya E.V., Shevchenko S.Y. Alternative treatment of patients with acute uncomplicated cystitis – whether the antibiotic is always necessary? Journal of Siberian Medical Sciences. 2016;(1):3. Russian (Кульчавеня Е.В., Шевченко С.Ю. Альтернативное лечение больных острым циститом – всегда ли нужен антибиотик? Journal of Siberian Medical Sciences. 2016;(1):3).
- Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014 Mar;28(1):1–13. doi: 10.1016/j.idc.2013.09.003. Epub 2013 Dec 8. PMID: 24484571.
- O’Brien V.P., Hannan T.J., Schaeffer A.J., Hultgren S.J. Are you experienced? Understanding bladder innate immunity in the context of recurrent urinary tract infection. Curr Opin Infect Dis. 2015 Feb;28(1):97–105. doi: 10.1097/QCO.0000000000000130. PMID: 25517222; PMCID: PMC4365976.
- Albert X., Huertas I., Pereiró I.I., Sanfélix J., Gosalbes V., Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;2004(3):CD001209. doi: 10.1002/14651858.CD001209.pub2. PMID: 15266443; PMCID: PMC7032641.
- Altarac S., Papeš D. Use of D-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women. BJU Int. 2014 Jan;113(1):9–10. doi: 10.1111/bju.12492. PMID: 24215164.
- Maki K.C., Nieman K.M., Schild A.L., Kaspar K.L., Khoo C. The Effect of Cranberry Juice Consumption on the Recurrence of Urinary Tract Infection: Relationship to Baseline Risk Factors. J Am Coll Nutr. 2018 Feb;37(2):121–126. doi: 10.1080/07315724.2017.1370398. Epub 2017 Nov 7. PMID: 29111902.
- Bruyère F., Azzouzi A.R., Lavigne J.P., Droupy S., Coloby P., Game X., Karsenty G., Issartel B., Ruffion A., Misrai V., Sotto A., Allaert F.A. A Multicenter, Randomized, Placebo-Controlled Study Evaluating the Efficacy of a Combination of Propolis and Cranberry (Vaccinium macrocarpon) (DUAB®) in Preventing Low Urinary Tract Infection Recurrence in Women Complaining of Recurrent Cystitis. Urol Int. 2019;103(1):41–48. doi: 10.1159/000496695. Epub 2019 May 22. PMID: 31117097.
- Koradia P., Kapadia S., Trivedi Y., Chanchu G., Harper A. Probiotic and cranberry supplementation for preventing recurrent uncomplicated urinary tract infections in premenopausal women: a controlled pilot study. Expert Rev Anti Infect Ther. 2019 Sep;17(9):733–740. doi: 10.1080/14787210.2019.1664287. Epub 2019 Sep 13. Erratum in: Expert Rev Anti Infect Ther. 2019 Nov;17(11):939. doi: 10.1080/14787210.2019.1673041. PMID: 31516055.
- Lenger SM, Bradley MS, Thomas DA, et al. D-Mannose vs other agents & for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol 2020; 223:265.e1 265.e13.
- Smith A.L., Brown J., Wyman J.F., Berry A., Newman D.K., Stapleton A.E. Treatment and Prevention of Recurrent Lower Urinary Tract Infections in Women: A Rapid Review with Practice Recommendations. J Urol. 2018 Dec;200(6):1174–1191. doi: 10.1016/j.juro.2018.04.088. Epub 2018 Jun 22. PMID: 29940246.
- Magistro G., Stief C.G. Vaccine Development for Urinary Tract Infections: Where Do We Stand? Eur Urol Focus. 2019 Jan;5(1):39–41. doi: 10.1016/j.euf.2018.07.034. Epub 2018 Aug 6. PMID: 30093359.
- Perrotta C., Aznar M., Mejia R., et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev 2008; CD005131.
- Goddard J.C., Janssen D.A.W. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta- analysis. Int Urogynecol J 2018; 29:933–942.
- Ali S.B., Perdawood D., Abdulrahman R., Al Farraj D.A., Alkubaisi N.A. Vitamin D deficiency as a risk factor for urinary tract infection in women at reproductive age. Saudi J Biol Sci. 2020 Nov;27(11):2942–2947. doi: 10.1016/j.sjbs.2020.08.008. Epub 2020 Aug 8. PMID: 33100850; PMCID: PMC7569126.
- Kranjčec B., Papeš D., Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014 Feb;32(1):79–84. doi: 10.1007/s00345-013-1091-6. Epub 2013 Apr 30. PMID: 23633128.
- Kotov S.V., Nemenov A.A., Perov R.A. Efficacy of combined phytotherapy (NefroBest® and UroBest®) in female patients with urolithiasis and preoperative drainage of upper urinary tract before ureteroscopy. Urology Herald. 2024;12(1):60–68. (In Russ.) https://doi.org/10.21886/2308-6424-2024-12-1-60-68. Russian (Котов С.В., Неменов А.А., Перов Р.А. Эффективность комбинированной фитотерапии (НефроБест® в сочетании с УроБест®) у женщин с уретеролитиазом на фоне дренирования мочевых путей перед уретероскопией. Вестник урологии. 2024;12(1):60–68. https://doi.org/10.21886/2308-6424-2024-12-1-60-68).
- Pan Y.T., Xu B., Rice K., Smith S., Jackson R., Elbein AD.. Specificity of the high-mannose recognition site between Enterobacter cloacae pili adhesin and HT-29 cell membranes. Infect Immun. 1997 Oct;65(10):4199–4206. doi: 10.1128/iai.65.10.4199-4206.1997. PMID: 9317027; PMCID: PMC175603.
- Jones C.H., Pinkner J.S., Roth R., Heuser J., Nicholes A.V., Abraham S.N., Hultgren S.J. FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2081–2085. doi: 10.1073/pnas.92.6.2081. PMID: 7892228; PMCID: PMC42427.
- Liu Y., Black M.A., Caron L., Camesano TA.. Role of cranberry juice on molecular-scale surface characteristics and adhesion behavior of Escherichia coli. Biotechnol Bioeng. 2006 Feb 5;93(2):297–305. doi: 10.1002/bit.20675. PMID: 16142789.
- Lavigne J.P., Vitrac X., Bernard L., Bruyère F., Sotto A. Propolis can potentialise the anti-ad- hesion activity of proanthocyanidins on uro- pathogenic Escherichia coli in the prevention of recurrent urinary tract infections. BMC Res Notes. 2011 Nov;4(1):522.
- Haghdoost S., Pazandeh F., Darvish S., Khabazkhoob M., Huss R. Lak T.B. Association of serum vitamin D levels and urinary tract infection in pregnant women: A case control study. Eur J Obstet Gynecol Reprod Biol. 2019 Dec; 243:51–56. doi: 10.1016/j.ejogrb.2019.10.015. Epub 2019 Oct 21. PMID: 31671292.
- Ali S.B., Perdawood D., Abdulrahman R., Al Farraj D.A., Alkubaisi N.A. Vitamin D deficiency as a risk factor for urinary tract infection in women at reproductive age. Saudi J Biol Sci. 2020 Nov;27(11):2942–2947. doi: 10.1016/j.sjbs.2020.08.008. Epub 2020 Aug 8. PMID: 33100850; PMCID: PMC7569126.
- Mahyar A., Ayazi P., Safari S., Dalirani R., Javadi A., Esmaeily S. Association between vitamin D and urinary tract infection in children. Korean J Pediatr. 2018 Mar;61(3):90–94. doi: 10.3345/kjp.2018.61.3.90. Epub 2018 Mar 19. PMID: 29628969; PMCID: PMC5876510.
- Seifi M., Abbasalizadeh S., Mohammad-Alizadeh-Charandabi S., Khodaie L., Mirghafourvand M. The effect of Rosa (L. Rosa canina) on the incidence of urinary tract infection in the puerperium: A randomized placebo-controlled trial. Phytother Res. 2018 Jan;32(1):76–83. doi: 10.1002/ptr.5950. Epub 2017 Oct 11. PMID: 29024081.
- Kontiokari T., Sundqvist K., Nuutinen M., Pokka T., Koskela M., Uhari M. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ. 2001 Jun 30;322(7302):1571. doi: 10.1136/bmj.322.7302.1571. PMID: 11431298; PMCID: PMC33514.
- Hakkola M., Vehviläinen P., Muotka J., Tejesvi M.V., Pokka T., Vähäsarja P., Hanni A.M., Renko M., Uhari M., Salo J., Tapiainen T. Cranberry-lingonberry juice affects the gut and urinary microbiome in children – a randomized controlled trial. APMIS. 2023 Mar;131(3):112–124. doi: 10.1111/apm.13292. Epub 2023 Jan 18. PMID: 36602283.
- Kylli P, Nohynek L, Puupponen-Pimiä R, Westerlund-Wikström B, Leppänen T, Welling J, Moilanen E, Heinonen M. Lingonberry (Vaccinium vitis-idaea) and European cranberry (Vaccinium microcarpon) proanthocyanidins: isolation, identification, and bioactivities. J Agric Food Chem. 2011 Apr 13;59(7):3373–3384. doi: 10.1021/jf104621e. Epub 2011 Mar 3. PMID: 21370878.
Supplementary files
